Trials / Completed
CompletedNCT00552305
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 as Adjunctive Therapy in Patients With Partial Seizures
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 370 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lacosamide | 50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial |
Timeline
- Start date
- 2001-08-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2007-11-01
- Last updated
- 2018-07-17
- Results posted
- 2011-09-02
Locations
59 sites across 8 countries: United States, Germany, Hungary, Lithuania, Poland, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00552305. Inclusion in this directory is not an endorsement.